Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Apr
22
Today In Oncology
2024 Annual Report to the Nation on the Status of Cancer Released
Adaptive Manufactured Lentiviral Anti-CD20 Anti-CD19 CAR T Cells in Relapsed Refractory Mantle Cell Lymphoma
Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma Lessons From CML
Updated CAP Guideline Aims to Address Rising Rates of HPV Associated Squamous Cell Carcinomas
Patient Support Found for AI Use as Second Reader of Mammograms
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo